Fulltext

Yaws

Marks, Michael ; Mitjà, Oriol ; Solomon, Anthony W. ; Asiedu, Kingsley B. ; Mabey, David C.

In: British Medical Bulletin, 2015, vol. 113, no. 1, p. 91-100

Ajouter à la liste personnelle
    Titre
    • Yaws
    Auteur
    • Marks, Michael. Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    • Mitjà, Oriol. Barcelona Centre for International Health Research, Hospital Clinic, University of Barcelona, Roselló 132, Barcelona, Spain
    • Solomon, Anthony W.. Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    • Asiedu, Kingsley B.. Department of Control of Neglected Tropical Diseases, World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland
    • Mabey, David C.. Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • British Medical Bulletin, 2015, vol. 113, no. 1, p. 91-100. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:295012
    Summary
    Introduction Yaws, caused by Treponema pallidum ssp. pertenue, is endemic in parts of West Africa, Southeast Asia and the Pacific. The WHO has launched a campaign based on mass treatment with azithromycin, to eradicate yaws by 2020. Sources of data We reviewed published data, surveillance data and data presented at yaws eradication meetings. Areas of agreement Azithromycin is now the preferred agent for treating yaws. Point-of-care tests have demonstrated their value in yaws. Areas of controversy There is limited data from 76 countries, which previously reported yaws. Different doses of azithromycin are used in community mass treatment for yaws and trachoma. Growing points Yaws eradication appears an achievable goal. The programme will require considerable support from partners across health and development sectors. Areas timely for developing research Studies to complete baseline mapping, integrate diagnostic tests into surveillance and assess the impact of community mass treatment with azithromycin are ongoing